Increasing Evidence Demonstrates the Usefulness of ctDNA

Education Award Recipients Recognized at Latin America Conference

TTLC 2023 Showcases Early Ongoing Trial Data, Newest Therapies

In Brief for Feb. 22, 2023

TTLC Keynote Speaker Explores Progress, Potential Breakthroughs of SCLC Therapies

Experts Debate TKI Use After Disease Progression for Patients with EGFR Mutations

Scenes from TTLC 2023

ILCN Editor Dr. Corey J. Langer Reflects on the ‘Fantastic Voyage’ From Nihilism to Hope in Thoracic Oncology

Specialists Debate the Merits of Lorlatinib as a Universal First-Line Treatment for ALK+ Patients

Study Explores First-Line Osimertinib for NSCLC Patients with Uncommon EGFR Mutations

New Texas Lung Cancer Conference Planned with Busy Clinicians in Mind

Mesothelioma Pioneer Delivers 2023 Heine H. Hansen Keynote Lecture